title: Prevalence, treatment and control of dyslipidaemia in Switzerland: still a long way to go.
abstract: BACKGROUND
  There is little information regarding the prevalence and management of dyslipidaemia in Switzerland.
  
  
  METHODS
  Cross-sectional population-based study of 3238 women and 2846 men aged 35-75.
  
  
  METHODS
  Dyslipidaemia prevalence, treatment and control were defined according to PROCAM guidelines adapted to Switzerland.
  
  
  RESULTS
  About 29% of the overall sample presented with dyslipidaemia, of which 39% were treated and 58% of those treated were controlled. Among the 710 patients with personal history of cardiovascular disease (CVD) and/or diabetes, 632 (89%) presented with dyslipidaemia, of which 278 (44%) and 134 (21%) patients were treated and adequately controlled, respectively. On multivariate analysis, hypolipidaemic drug treatment was positively related with age and body mass index (P for trend <0.001), and negatively related with smoking status (P for trend <0.002), whereas personal history of CVD and/or diabetes had no effect [odds ratio (OR)=1.12, 95% confidence interval (CI): 0.90-1.38]. Adequate control of lipid levels was negatively related with female sex (OR=0.65, 95% CI: 0.45-0.94) and personal history of CVD and/or diabetes (OR=0.42, 95% CI: 0.30-0.59). When personal history of CVD and/or diabetes was replaced by PROCAM risk categories, patients in the highest risk were also less well controlled.
  
  
  CONCLUSIONS
  In this population-based study, one-third of the participants was dyslipidaemic, but less than half was treated and only one-fifth was adequately controlled. The low treatment and control levels among individuals at high risk for CVD calls for a better application of recommendations regarding personal preventive measures.
authors.affiliation: Department of Medicine, Centre for Cardiovascular and Metabolic Research (Cardiomet), University Hospital, University of Lausanne, Lausanne, Switzerland.
authors.forename: Mathieu
authors.initials: M
authors.lastname: Firmann
authors.forename: Pedro
authors.initials: P
authors.lastname: Marques-Vidal
authors.forename: Fred
authors.initials: F
authors.lastname: Paccaud
authors.forename: Vincent
authors.initials: V
authors.lastname: Mooser
authors.forename: Nicolas
authors.initials: N
authors.lastname: Rodondi
authors.forename: Gérard
authors.initials: G
authors.lastname: Waeber
authors.forename: Peter
authors.initials: P
authors.lastname: Vollenweider
mesh_terms: D000328:Adult; D000368:Aged; D002318:Cardiovascular Diseases / Q000453:epidemiology; D016009:Chi-Square Distribution; D003430:Cross-Sectional Studies; D003920:Diabetes Mellitus / Q000453:epidemiology; D050171:Dyslipidemias / Q000188:drug therapy* / Q000453:epidemiology* / Q000517:prevention & control; D005260:Female; D019983:Guideline Adherence; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D017410:Practice Guidelines as Topic; D015995:Prevalence; D018570:Risk Assessment; D012307:Risk Factors; D013557:Switzerland / Q000453:epidemiology; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000960:Hypolipidemic Agents